Markets:

Overview

News

Currencies

International

Treasuries

Organon & Co. Common Stock (NY:OGN)

7.750 +0.240 (+3.20%)

Streaming Delayed Price Updated: 11:30 AM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

121 Stocks That Hit Their 52-Week Low ↗

October 14, 2022

New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.

Via Benzinga

Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings ↗

August 04, 2022

Via Benzinga

Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval ↗

April 08, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022 ↗

October 14, 2022

Upgrades

Via Benzinga

Netflix To Gain Around 8%? Plus This Analyst Slashes PT On Five9 By About 50% ↗

October 14, 2022

UBS boosted Netflix, Inc. (NASDAQ: NFLX) price target from $198 to $250. Netflix shares rose 5.3% to close at $232.51 on Thursday.

Via Benzinga

No Need To Call A Broker: Real Estate NFTs Let Homeowners Cut Out The Middleman Via Roofstock and Origin Protocol ↗

October 06, 2022

The $11 trillion real estate market remains a much talked about industry for streamlining access, reducing transaction friction, and democratizing ownership. Real estate technology company Roofstock...

Via Benzinga

How Is The Market Feeling About Organon? ↗

October 06, 2022

Organon's (NYSE:OGN) short percent of float has risen 11.91% since its last report. The company recently reported that it has 5.94 million shares sold short, which is 2.63% of all regular shares that...

Via Benzinga

After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff ↗

September 13, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022 ↗

September 06, 2022

Upgrades

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

September 07, 2022

On Wednesday, 297 companies achieved new lows for the year.

Via Benzinga

This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73% ↗

September 06, 2022

Raymond James cut the price target for PolyPid Ltd. (NASDAQ: PYPD) from $15 to $4. PolyPid shares fell 7.7% to $1.32 in pre-market trading.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

August 31, 2022

On Wednesday, 238 companies achieved new lows for the year.

Via Benzinga

This Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring' ↗

August 30, 2022

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 17, 2022

Via Benzinga

Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)

August 17, 2022

From Organon & Co.

Via Business Wire

A Look Into Healthcare Sector Value Stocks ↗

August 15, 2022

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗

August 05, 2022

Upgrades

Via Benzinga

Organon: Q2 Earnings Insights ↗

August 04, 2022

Organon (NYSE:OGN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Organon reported in-line EPS of $1.25...

Via Benzinga

Organon Reports Results for the Second Quarter Ended June 30, 2022

August 04, 2022

From Organon & Co.

Via Business Wire

Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

July 28, 2022

From Organon & Co.

Via Business Wire

Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022

July 21, 2022

From Organon & Co.

Via Business Wire

Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange ↗

June 18, 2022

Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global...

Via Talk Markets

Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates

June 13, 2022

From Organon & Co.

Via Business Wire

On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report

June 02, 2022

From Organon & Co.

Via Business Wire

Market Selloff ↗

May 10, 2022

In a U.S. market selloff, the strong performance of mostly foreign issues was impressive.

Via Talk Markets

Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up ↗

May 05, 2022

The firm's biggest product sustained a hit due to exchange rates and buying patterns.

Via Investor's Business Daily

Organon Reports Results for the First Quarter Ended March 31, 2022

May 05, 2022

From Organon & Co.

Via Business Wire

Organon To Report First Quarter Results and Host Conference Call on May 5, 2022

April 21, 2022

From Organon & Co.

Via Business Wire

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment ↗

March 31, 2022

Organon & Co (NYSE: OGN)

Via Benzinga

Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)

March 31, 2022

From Organon & Co.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.